![Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | Fierce Pharma Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1631008555/K%C3%A5re_Schultz.jpg/K%C3%A5re_Schultz.jpg?VersionId=s_4t9O_vhJMy8UzGnAAupmDB6ZEtTLiG)
Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | Fierce Pharma
![Teva Pharmaceuticals and MedinCell gain FDA approval for UZEDY, the first subcutaneous, long-acting formulation of risperidone for the treatment of schizophrenia in adults. Teva Pharmaceuticals and MedinCell gain FDA approval for UZEDY, the first subcutaneous, long-acting formulation of risperidone for the treatment of schizophrenia in adults.](https://news-media.coinunited.io/news/uploads/2023/04/29133220/cunews-teva-pharmaceuticals-and-medincell-gain-fda-approval-for-uzedy-the-first-subcutaneous-long-acting-formulation-of-risperidone-for-the-treatment-of-schizophrenia-in-adults-scaled.webp)
Teva Pharmaceuticals and MedinCell gain FDA approval for UZEDY, the first subcutaneous, long-acting formulation of risperidone for the treatment of schizophrenia in adults.
![Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ | SnackSafely.com Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ | SnackSafely.com](https://media.snacksafely.com/wp-content/uploads/2019/07/Digihaler.jpg)
Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ | SnackSafely.com
![Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets | Business Wire Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets | Business Wire](https://mms.businesswire.com/media/20230217005357/en/739014/23/teva_RGB_JPEG.jpg)
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets | Business Wire
![Teva Pharmaceutical | $TEVA Stock | Shares Rally After Winning FDA Approval for Migraine Therapy - Warrior Trading News Teva Pharmaceutical | $TEVA Stock | Shares Rally After Winning FDA Approval for Migraine Therapy - Warrior Trading News](https://marketexclusive.com/wp-content/uploads/2017/02/Teva-Pharmaceutical-Industries-Ltd.jpg)
Teva Pharmaceutical | $TEVA Stock | Shares Rally After Winning FDA Approval for Migraine Therapy - Warrior Trading News
![MedinCell's Partner Teva Today Announced Refiling for Approval of mdc-IRM and Confirmed Planned Launch in the U.S. in H1 2023 | Business Wire MedinCell's Partner Teva Today Announced Refiling for Approval of mdc-IRM and Confirmed Planned Launch in the U.S. in H1 2023 | Business Wire](https://mms.businesswire.com/media/20221103006276/en/1625415/23/Logo_MedinCell_registered.jpg)